This is the title of my Fast Facts presentation at ISPOR Europe with Tiago Beck on Tuesday, November 11 at 11:30 GMT. If you’re in Glasgow next week, feel free to stop by this session. Should be interesting. The gist is below.
As trilateral negotiations on the EU pharmaceutical package progress, stakeholders across the healthcare ecosystem are watching closely. This amendment aims to reshape incentives, regulatory pathways and access mechanisms across Europe – with direct impacts on payers, HTA bodies, industry and patients. In this quick facts session, we’ll explain where the legislative process currently stands and what the key issues will shape the final agreement. Areas of focus include: 1) progress and timelines in the triad phase; 2) potential impact on data and market security; 3) Revised incentives for orphan and pediatric drugs; 4) interaction with the EU’s industrial and competitiveness objectives; and 5) potential implications for national level pricing, reimbursement, and access. With important decisions ahead, this session provides a brief policy snapshot to understand where the EU pharma package is headed and why it is important for health economists and payers alike.
Full session details here.
